Painchek Ltd · ASX:PCK
Painchek — Investor Presentation (January 2024)
35 slides from Painchek's investor presentation, Jan 30, 2024
Slide 1: Investor Webinar Presentation
ASX ANNOUNCEMENT 30 January 2024 INVESTOR WEBINAR PRESENTATION TUESDAY, 30 JANUARY 2024 Further to the webinar announcement on 29th January, PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is please
Slide 2: PainChek Shared Care Program
The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review. To find out more, visit
Slide 3: Quarterly Update January 2024
For personal use only Quarterly Update January 2024 PHILIP DAFFAS, CEO & MD PAINCHEK LTD | ASX:PCK 1 |
Slide 4: Our purpose is to give a voice to people who cannot reliably verbalise their pain
For personal use only Our purpose is to give a voice to people who cannot reliably verbalise their pain
Slide 5: The Evolution of Pain Assessment
THE EVOLUTION OF PAIN ASSESSMENT Legacy Pain For personal use only PainChek® Assessment Tools “The PainChek app, which I see as a welcome evolutionary development of my past work, was introduced to improve painmanagement practices by ensuringan evidence-based assessment of pain could bemade at the p
Slide 6: The PainChek Universal App: Quick and Easy Operation
THE PAINCHEK® UNIVERSAL APP: QUICK AND EASY OPERATION AI based micro-facial pain expression analysis: For personal use only A medical • 3 second scan of patient face device in • recognises 9 micro-facial your pocket expressions indicative of pain Guided Digital questionnaire checklist: • guides the
Slide 7: The Breadth of PainChek's Global Market Opportunity
THE BREADTH OF PAINCHEK’s GLOBAL MARKET OPPORTUNITY For personal use only 400M pre-verbal children1 25-42% of hospital beds occupied by people with dementia4,5 57M people living with dementia >150M expected by 20502,3 1. Ecology Communications Group. www.ecology.com/birth-death-rates 4. Tsai, I. P.,
Slide 8: PainChek Well Positioned to Exploit Large Global Market Opportunities
PAINCHEK WELL POSITIONED TO EXPLOIT LARGE GLOBAL MARKET OPPORTUNITES For personal use only AGED CARE MARKET HOME CARE INFANT MARKET HOSPITAL MARKET 6 MILLION BEDS 1 UP TO 10X AGED 400M PRE-VERBAL ~$1Bn ANNUALLY 4 CARE MARKET 2 CHILDREN & - 150M ANNUALLY TO $300M ANNUAL FIRST TIME PARENTS 3 ARR 2 1.
Slide 9: Highlights – December 2023 Quarter
HIGHLIGHTS – DECEMBER 2023 QUARTER For personal use only More than 25,000 contracted licenses Strong pipeline of pilot UK GROWTH (ARR of $1.22M fully implemented) – programs and contracts RAMPING UP 29% growth on prior quarter under negotiation Continued Reinforced by Overall – 85,368 PainChek well
Slide 10: Consecutive Quarter of Double Digit Licence Growth
5 TH C O N S E C U T I V E Q U A R T E R O F DOUBLE DIGIT LICENCE GROWTH For personal use only WW CONTRACTED LICENCES LICENCES / ARR $M $3.90 60% increase in ARR1 over the prior year 90,000 $4.00 $3.67 $3.41 80,000 SAAS business model with 70-85% % $3.50 $3.06 gross margins2 on annual licences 70,00
Slide 11: UK Growth Continues Acceleration
UK GROWTH CONTINUES ACCELERATION For personal use only WOR LD WI D E CON T R A CT ED 90,000 LI CEN CES 85,368 80,000 77,037 70,007 153% increase in UK contracted beds to more 25,073 70,000 64,163 than 25,000 beds over prior year 19,367 60,000 55,254 18,834 15,110 Untapped potential in 50,000 9,900 U
Slide 12: Consistent Growth in Utility
CONSISTENT GROWTH IN UTILITY For personal use only CUMULATIVE NUMBER OF PAINCHEK® ASSESSMENTS 4,500,000 4,120,000 4,000,000 Over 4.1 million global pain assessments conducted on the PainChek platform 3,450,000 3,500,000 2,950,000 3,000,000 122% increase in global pain assessments over the previous y
Slide 13: PainChek Around the World and Across Australia
PAINCHEK AROUND THE WORLD ….AND ACROSS AUSTRALIA 85,000 Licences, 1400 FACILITIES ACROSS 3 CONTINENTS Canada Europe (EU) For personal use only • Regulatory cleared • Regulatory cleared & Patent secured • Initial commercial • Establishing commercial partner contacts in clients now major markets (D, F
Slide 14: PainChek Across Australia
PAINCHEK ACROSS AUSTRALIA AGED CARE’s MOST POPULAR DIGITAL CLINICAL TOOL Aged Care PainChek commercial licences cover more than 57,000 beds and 790 For personal use only aged care homes, over 32% of total AU market and growing with a current retention rate of 92%. Retirement Living & Home Care PainC
Slide 15: PainChek's Growing UK Footprint in a 500,000 Bed Market
PAINCHEK’S GROWING UK FOOTPRINT IN A 500,000 BED MARKET • PainChek commercial licences in UK aged care cover more than 25,000 beds, 600 care homes, and 97 organisations For personal use only • New clients during the quarter include WeCare (1,500 beds) • Endorsed by Scotland’s regulator as a key tech
Slide 16: Integration Partners Provide Access to 1,500,000 Beds
PAINCHEK’S EXISTING CMS & MEDICATION MANAGEMENT AND INTEGRATION PARTNERS PROVIDE ACCESS TO 1,500,000 BEDS PainChek integrates and works with aged care management and medication management systems covering more than 180,000 For personal use only aged care beds in Australia, 25,000 beds in New Zealand
Slide 17: Scottish Care Inspectorate Independent Evaluation
For personal use only SCOTTISH CARE INSPECTORATE INDEPENDENT EVALUATION 15 |
Slide 18: Scottish Care Inspectorate Phase 1 Outcomes
SCOTTISH CARE INSPECTORATE P A I N C H E K - 1 st P H A S E O U T C O M E S "We welcome the use of innovation and technology to help support people to experience the best possible care.” For personal use only “This device should enable more appropriate use of medication and improved quality of life
Slide 19: PainChek Featured in Frontiers in Psychiatry Publication
For personal use only ORCHARD CARE HOMES PAINCHEK FEATURED IN INTERNATIONAL JOURNAL ‘FRONTIERS IN PSYCHIATRY’ PUBLICATION https://www.painchek.com/wp-content/uploads/2023/12/Baird-et-al-2023-Clinical-impact.the-Reconnect-Program.pdf 17 |
Slide 20: PainChek Helping to Improve Pain Management Outcomes in U.K.
PAINCHEK HELPING TO IMPROVE PAIN MANAGEMENT OUTCOMES IN U.K. For personal use only Implementation of Pain management Medication & QoL PainChek across 24 improvements improvements homes & 1,365 beds • 100% increase in frequency • 33% reduction of of pain assessments antipsychotic drug use (46% stoppe
Slide 21: Market Partnerships and Drivers for USA & Canada
MARKET PARTNERSHIPS AND DRIVERS FOR USA & CANADA For personal use only PAINCHEK IS TARGETING FDA DE NOVO CLEARANCE AND US LAUNCH IN 2024 NORTH AMERICAN LONG TERM CARE PointClickCare: PainChek integrated MARKET OPPORTUNITY with PointClickCare leading long term care provider in USA & Canada – USA – 15
Slide 22: North America Updates Q1 CY24
NORTH AMERICA UPDATES Q1 CY24 For personal use only US FDA de Novo study – progressing in New York & Iowa with data collection expected Q1 CY24 – FDA submission to follow shortly thereafter PointClickCare US aged care client conference – PainChek attending in February as part of US pre-launch market
Slide 23: PainChek Analytics
PAINCHEK ANALYTICS REAL TIME INSIGHTS AT YOUR FINGERTIPS For personal use only HOW DIGITAL ANALYTI CS SUPPORTS PERSON CENTRED PAIN MANAGEMENT 21
Slide 24: PainChek: Enabling Personal Pain Profiling
PAINCHEK: ENABLING PERSONAL PAIN PROFILING John David For personal use only PainChek® Pain Score Pain intensity 0 to 6 No Pain 7 to 11 Mild Pain 77 years old, advanced 70 years old, advanced Alzheimer Dementia, 12 to 15 Moderate Pain Alzheimer Dementia, recent osteoarthritis, unable to injury, unabl
Slide 25: PainChek: Enabling Personal Pain Profiling – John
PAINCHEK: ENABLING PERSONAL PAIN PROFILING John For personal use only 23
Slide 26: PainChek: Enabling Personal Pain Profiling – David
PAINCHEK: ENABLING PERSONAL PAIN PROFILING David For personal use only 24
Slide 27: John's and David's Pain Experience
PAINCHEK: ENABLING PERSONAL PAIN PROFILING John’s pain experience David’s pain experience For personal use only A d v a n c ed A D , o s t eo ar t h r i t i s , A d v a n c ed A D , r e c e n t i n j u r y , m o d era t e p a i n , i n a c t i v e - m o d era t e p a i n , v e r b a l l y p r o l o
Slide 28: The Past, the Present and the Shape of Things to Come
THE PAST, THE PRESENT AND THE SHAPE OF THINGS TO COME Personalizing pain management Global PainChek Personalization For personal use only population Pain Management PainChek Pain Profiling • Clinical Decision support Assessing & Documenting pain pathways to optimise Consumer treatment in all clinica
Slide 29: PainChek Infant Progress
PAINCHEK INFANT PROGRESS TARGETING MARKET OF 400M PRE-VERBAL CHILDREN AND 150 MILLION BORN EACH YEAR TO FIRST TIME PARENTS For personal use only Updated head movement Direct to Consumer New AI vocalisation Marketing feature feature • Updated adaptive • Completion of new • Australian initial market v
Slide 30: PainChek Infant: Making Infant Pain Visible and Audible
PAINCHEK® INFANT MAKING INFANT PAIN VISIBLE…AND AUDIBLE For personal use only 1. 2. 3. 4. 5. 1 Parent or Caregiver PainChek® Infant Facial PainChek® Infant Parent or Caregiver uses hears an technology measures Vocalisation technology Parent or Caregiver PainChek® Infant to Infant’s cry and monitors
Slide 31: PainChek Upcoming Catalysts
PAINCHEK UPCOMING CATALYSTS For personal use only Continued acceleration of sales and ARR Complete FDA studies in Q1 C2024 growth within RAC, Retirement and Home and submit to obtain US FDA De Care setting in ANZ, UK, Canada and new Novo clearance in CY 24 EU opportunities in CY 24 Enter global hosp
Slide 32: Corporate Summary
CORPORATE SUMMARY Top shareholders % For personal use only Financial information Peters Investments Proprietary Ltd 8.3% Share price (29 January 2024) A$0.036 Founders 5.3% Shares on issue 1,435.8m Board & key staff 4.5% Market capitalisation A$51.7m Cash (31 December 2023) A$2.0m Unlisted options/p
Slide 33: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hoggan Iain McAdam CEO & Managing Chief Scientific Head of Operations CFO Director, MBA, BSc Officer PhD, MPS Philip is a highly accomplished Jeff is a professor in the Andy is a Psychologist, Iain has over 20 years finance & glob
Slide 34: The Board
THE BOARD For personal use only John Murray Philip Daffas Ross Harricks Adam Davey Cynthia Payne Non-Exec Chair CEO & Managing Non-Exec Director Non-Exec Director Non-Exec Director Director 25 years in tech & Philip is a highly Senior global medical Corporate finance 30 years executive Venture Capit
Slide 35: Contact
For personal use only Quarterly Update January 2024 CONTACT Philip Daffas, CEO & MD philip.da ffa s@ painc hek. co m P A I N C H E K L T D | A S X : P C33 K